Dare Bioscience Inc
$ 2.95
8.46%
17 Apr - close price
- Market Cap 42,950,500 USD
- Current Price $ 2.95
- High / Low $ 3.43 / 2.49
- Stock P/E N/A
- Book Value 0.20
- EPS -1.20
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -25.43 %
- 52 Week High 3.43
- 52 Week Low 1.27
About
Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$9.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-27 | 2025-11-13 | 2025-08-14 | 2025-05-05 | 2025-03-26 | 2024-11-07 | 2024-08-08 | 2024-05-14 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.1006 | -0.28 | -0.45 | -0.5 | -0.65 | -0.55 | -0.88 | -0.07 | -0.06 | -0.09 | -0.1 | -0.09 |
| Estimated EPS | -0.42 | 0.02 | 0.03 | -0.58 | -0.6333 | -0.73 | 0.02 | -0.06 | -0.1 | -0.1 | -0.1 | -0.1 |
| Surprise | 0.3194 | -0.3 | -0.48 | 0.08 | -0.0167 | 0.18 | -0.9 | -0.01 | 0.04 | 0.01 | 0 | 0.01 |
| Surprise Percentage | 76.0476% | -1500% | -1600% | 13.7931% | -2.637% | 24.6575% | -4500% | -16.6667% | 40% | 10% | 0% | 10% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DARE
2026-04-20 23:39:06
Dare Bioscience (NASDAQ:DARE) has completed a closing of its Regulation A offering, issuing 20,000 Investor Units, each comprising one share of Series A Convertible Preferred Stock and two warrants, at $5.00 per unit. This capital raise is crucial as the company, despite having more cash than debt, is rapidly burning through its reserves. Analysts maintain a bullish outlook on DARE, with price targets ranging from $8 to $12.
2026-04-20 19:39:06
Daré Bioscience (NASDAQ: DARE) has completed a closing of its Regulation A offering, selling 20,000 Investor Units at $5.00 per unit. Each unit consists of one share of Series A Convertible Preferred Stock and two Investor Warrants, allowing for the purchase of up to 40,000 common shares. This offering was conducted under a Form 1-A filing most recently qualified by the SEC on April 1, 2026.
2026-04-19 11:33:00
Daré Bioscience (DARE) has seen its stock surge by 8.89% due to optimism surrounding its women's reproductive health pipeline. Key near-term catalysts include the Q2 2026 launch of DARE to PLAY and Flora Sync LF5, along with progress in Ovaprene Phase 3 trials and ARPA-H-backed DARE-HPV advancement. Despite current negative margins and reliance on future funding, the company's strong gross margin and upcoming product launches offer asymmetric upside for risk-tolerant traders.
2026-04-18 16:09:08
DARE Bioscience Inc. (NASDAQ: DARE) saw an 8.89% stock surge driven by upcoming clinical development news and product launches. The company, a micro-cap women's health firm, is focusing on near-term catalysts including the launch of DARE to PLAY sildenafil cream and Flora Sync LF5 probiotic in Q2 2026, alongside progress in its Ovaprene and DARE-HPV pipelines. Despite being loss-making, the company's asset-light commercialization strategy and these catalysts are attracting speculative interest, though financing risk remains.
2026-04-18 11:06:00
Dare Bioscience Inc. (DARE) stock surged by 8.89% after recent clinical progress, including the launch of DARE to PLAY and Flora Sync LF5, boosted investor confidence. Despite strong short-term trading momentum and catalyst-driven price action, an analyst noted significant underlying risks due to its micro-cap status, negative profitability, and reliance on future pipeline success rather than current revenues. The stock's valuation is largely based on its women's health pipeline and ARPA-H backing, with a near-term downside risk highlighted.
2026-04-17 20:10:15
Daré Bioscience (DARE) announced an 8-K filing detailing the reclassification of director Gregory W. Matz. This change involves his voluntary resignation as a Class II director and simultaneous reappointment as a Class III director, solely to rebalance the company's six-member staggered board. Matz, along with Sabrina Martucci Johnson, will stand for re-election at the 2026 annual meeting of stockholders, with his service considered continuous and his committee assignments unchanged.
